[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-31429":3,"doc-seo-31429":27},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"file_id":15,"file_url":16,"file_type":17,"file_size":18,"view_count":4,"is_deleted":4,"is_public":19,"is_downloadable":19,"audit_status":19,"page_count":20,"language":21,"language_code":22,"table_of_contents":23,"faqs":24,"seo_title":13,"seo_description":14,"update_tm":25,"read_time":26},31429,962075006959,"Anda","https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297",8,"Research & Report","A Metal–Organic Framework-Based Co-Delivery System for Atherosclerosis Therapy via Macrophage Regulation","A metal–organic framework nanocarrier co-delivery strategy targets macrophage-driven atherosclerosis progression by combining fragile histidine triad protein (FHIT) with a copper-tetrakis(4-carboxyphenyl)porphyrin (Cu-TCPP) MOF. The system is designed to act primarily on macrophages and, through mechanistic actions, increases reactive oxygen species (ROS) and suppresses the PI3K/AKT signaling pathway, culminating in macrophage apoptosis. In vivo results show reduced atherosclerotic lesions, supporting therapeutic potential for improved disease management.","cbCaie25bUyJR4DM","https://ap.wps.com/l/cbCaie25bUyJR4DM","pdf",5621916,1,18,"English","en","# Introduction","[{\"question\":\"What co-delivery system is developed for atherosclerosis therapy?\",\"answer\":\"A nanocarrier system co-delivers fragile histidine triad protein (FHIT) and a Cu-TCPP metal–organic framework (Cu-TCPP MOF) to target macrophages in atherosclerosis.\"},{\"question\":\"How does the FHIT + Cu-TCPP MOF treatment affect macrophages mechanistically?\",\"answer\":\"The combined application increases reactive oxygen species (ROS) production, inhibits the PI3K/AKT signaling pathway, and induces macrophage apoptosis.\"},{\"question\":\"What evidence supports the treatment’s therapeutic potential in vivo?\",\"answer\":\"In vivo studies demonstrate that the combined treatment effectively reduces atherosclerotic lesions, indicating therapeutic potential for atherosclerosis management.\"}]",1779483644,45,{"code":4,"msg":28,"data":29},"ok",{"site_id":30,"language":22,"slug":31,"title":13,"keywords":32,"description":14,"schema_data":33,"social_meta":84,"head_meta":86,"extra_data":88,"updated_unix":25},105,"a-metalorganic-framework-based-co-delivery-system-for-atherosclerosis-therapy-via-macrophage-regulation","",{"@graph":34,"@context":83},[35,52,66],{"@type":36,"itemListElement":37},"BreadcrumbList",[38,42,46,49],{"item":39,"name":40,"@type":41,"position":19},"https://docshare.wps.com","Home","ListItem",{"item":43,"name":44,"@type":41,"position":45},"https://docshare.wps.com/document/","Document",2,{"item":47,"name":12,"@type":41,"position":48},"https://docshare.wps.com/document/research-report/",3,{"item":50,"name":13,"@type":41,"position":51},"https://docshare.wps.com/document/a-metalorganic-framework-based-co-delivery-system-for-atherosclerosis-therapy-via-macrophage-regulation/31429/",4,{"url":50,"name":13,"@type":53,"author":54,"headline":13,"publisher":56,"fileFormat":59,"description":14,"dateModified":60,"datePublished":60,"encodingFormat":59,"isAccessibleForFree":61,"interactionStatistic":62},"DigitalDocument",{"name":9,"@type":55},"Person",{"url":39,"name":57,"@type":58},"DocShare","Organization","application/pdf","2026-05-22",true,{"@type":63,"interactionType":64,"userInteractionCount":4},"InteractionCounter",{"@type":65},"ViewAction",{"@type":67,"mainEntity":68},"FAQPage",[69,75,79],{"name":70,"@type":71,"acceptedAnswer":72},"What co-delivery system is developed for atherosclerosis therapy?","Question",{"text":73,"@type":74},"A nanocarrier system co-delivers fragile histidine triad protein (FHIT) and a Cu-TCPP metal–organic framework (Cu-TCPP MOF) to target macrophages in atherosclerosis.","Answer",{"name":76,"@type":71,"acceptedAnswer":77},"How does the FHIT + Cu-TCPP MOF treatment affect macrophages mechanistically?",{"text":78,"@type":74},"The combined application increases reactive oxygen species (ROS) production, inhibits the PI3K/AKT signaling pathway, and induces macrophage apoptosis.",{"name":80,"@type":71,"acceptedAnswer":81},"What evidence supports the treatment’s therapeutic potential in vivo?",{"text":82,"@type":74},"In vivo studies demonstrate that the combined treatment effectively reduces atherosclerotic lesions, indicating therapeutic potential for atherosclerosis management.","https://schema.org",{"og:url":50,"og:type":85,"og:title":13,"og:site_name":57,"og:description":14},"article",{"robots":87,"canonical":50},"index,follow",{"doc_id":7,"site_id":30}]